This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schindler, J. Articles by Vitetta, E. S. Search for Related Content PubMed PubMed Citation Articles by Schindler, J. Articles by Vitetta, E. S.

The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin’s Lymphoma Is Exacerbated by Prior Radiotherapy: A Retrospective Analysis of Patients in Five Clinical Trials¹

The Cancer Immunobiology Center and the Department of Microbiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 [J. S., J. W. U., E. S. V.], and the Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland [E. S., R. M.]

A retrospective analysis of 102 patients with relapsed, non-Hodgkin’s lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.

This article has been cited by other articles:

				M. Kugler, C. Stein, M. Schwenkert, D. Saul, L. Vockentanz, T. Huber, S. K. Wetzel, O. Scholz, A. Pluckthun, A. Honegger, et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework Protein Eng. Des. Sel., March 1, 2009; 22(3): 135 - 147. [Abstract] [Full Text] [PDF]

				D A Vallera, B J Stish, Y Shu, H Chen, A Saluja, D J Buchsbaum, and S M Vickers Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model Gut, May 1, 2008; 57(5): 634 - 641. [Abstract] [Full Text] [PDF]

				T. Wang, J. Zhao, J.-L. Ren, L. Zhang, W.-H. Wen, R. Zhang, W.-W. Qin, L.-T. Jia, L.-B. Yao, Y.-Q. Zhang, et al. Recombinant Immunoproapoptotic Proteins with Furin Site Can Translocate and Kill HER2-Positive Cancer Cells Cancer Res., December 15, 2007; 67(24): 11830 - 11839. [Abstract] [Full Text] [PDF]

				Y.-H. Wu, S.-F. Shih, and J.-Y. Lin Ricin Triggers Apoptotic Morphological Changes through Caspase-3 Cleavage of BAT3 J. Biol. Chem., April 30, 2004; 279(18): 19264 - 19275. [Abstract] [Full Text] [PDF]

				M. A. Olson, J. H. Carra, V. Roxas-Duncan, R. W. Wannemacher, L. A. Smith, and C. B. Millard Finding a new vaccine in the ricin protein fold Protein Eng. Des. Sel., April 1, 2004; 17(4): 391 - 397. [Abstract] [Full Text] [PDF]

				J. F. DiJoseph, D. C. Armellino, E. R. Boghaert, K. Khandke, M. M. Dougher, L. Sridharan, A. Kunz, P. R. Hamann, B. Gorovits, C. Udata, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies Blood, March 1, 2004; 103(5): 1807 - 1814. [Abstract] [Full Text] [PDF]

				R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma Ann. Onc., May 1, 2003; 14(5): 729 - 736. [Abstract] [Full Text] [PDF]

				J. A. Posey, M. B. Khazaeli, M. A. Bookman, A. Nowrouzi, W. E. Grizzle, J. Thornton, D. E. Carey, J. M. Lorenz, A. P. Sing, C. B. Siegall, et al. A Phase I Trial of the Single-Chain Immunotoxin SGN-10 (BR96 sFv-PE40) in Patients with Advanced Solid Tumors Clin. Cancer Res., October 1, 2002; 8(10): 3092 - 3099. [Abstract] [Full Text] [PDF]

				R. Schnell, O. Staak, P. Borchmann, C. Schwartz, B. Matthey, H. Hansen, J. Schindler, V. Ghetie, E. S. Vitetta, V. Diehl, et al. A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma Clin. Cancer Res., June 1, 2002; 8(6): 1779 - 1786. [Abstract] [Full Text] [PDF]

				A. E. Frankel Increased Sophistication of Immunotoxins Clin. Cancer Res., April 1, 2002; 8(4): 942 - 944. [Full Text] [PDF]

				S. P. Christiansen, D. Peterson, T. To, R. Youle, and L. McLoon Long-term Effects of Ricin-mAb 35 on Extraocular Muscles of Rabbits: Potential Treatment for Strabismus Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 679 - 685. [Abstract] [Full Text] [PDF]